Reviewing once more the c-myc and Ras collaboration: Converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology

Cell Cycle

Volumn 10, Issue 1, 2011, Pages 57-67

  Wang, Chenguang ^a   Lisanti, Michael P ^a   Liao, D Joshua ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

c Myc; Cyclin D1; Immortalization; Oncogene; Transformation

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; RAS PROTEIN;

APOPTOSIS; CANCER CELL CULTURE; CARCINOGENICITY; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL SURVIVAL; CELL TRANSFORMATION; DNA FLANKING REGION; EPITHELIUM CELL; FIBROBLAST; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; GENETIC MARKER; HUMAN; KNOCKOUT MOUSE; MUTANT; MUTATION; NEOPLASM; ONCOGENE; ONCOGENE C MYC; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; REVIEW; SQUAMOUS CELL; TRANSGENE;

ANIMALIA;

EID: 78650828153     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.1.14449     Document Type: Review

References (194)

1. Liao D, Thakur A, Wu J, Biliran H, Sarkar FH. Perspectives on c-Myc, cyclin D1, and their interaction in cancer formation, progression and response to chemotherapy. Crit Rev Oncog 2007; 13:93-158. (Pubitemid 350274298)
2. Laurenti E, Wilson A, Trumpp A. Myc's other life: stem cells and beyond. Curr Opin Cell Biol 2009; 21:844-54.
3. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001; 1:157-62.
4. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983; 304:596-602. (Pubitemid 13035496)
5. Kelekar A, Cole MD. Immortalization by c-myc, H-ras and Ela oncogenes induces differential cellular gene expression and growth factor responses. Mol Cell Biol 1987; 7:3899-907.
6. Mougneau E, Lemieux L, Rassoulzadegan M, Cuzin F. Biological activities of v-myc and rearranged c-myc oncogenes in rat fibroblast cells in culture. Proc Natl Acad Sci USA 1984; 81:5758-62.
7. Drissi R, Zindy F, Roussel MF, Cleveland JL. c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells. J Biol Chem 2001; 276:29994-30001.
8. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, Adams RR, et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999; 18:1219-26. (Pubitemid 29085995)
9. Kohl NE, Ruley HE. Role of c-myc in the transformation of REF52 cells by viral and cellular oncogenes. Oncogene 1987; 2:41-8.
10. Simm A, Halle JP, Adam G. Proliferative and metabolic capacity of rat embryo fibroblasts immortalized by c-myc depends on cellular age at oncogenic transfection. Eur J Cell Biol 1994; 65:121-31.
11. Zoidl G, Brockmann D, Esche H. Deletion of the beta-turn/alpha-helix motif at the exon 2/3 boundary of human c-Myc leads to the loss of its immortalizing function. Gene 1993; 131:269-74. (Pubitemid 223033429)
12. Benanti JA, Wang ML, Myers HE, Robinson KL, Grandori C, Galloway DA. Epigenetic downregulation of ARF expression is a selection step in immortalization of human fibroblasts by c-Myc. Mol Cancer Res 2007; 5:1181-9.
13. De Filippis L, Ferrari D, Rota NL, Amati B, Snyder E, Vescovi AL. Immortalization of human neural stem cells with the c-myc mutant T58A. PLoS One 2008; 3:3310.
14. Miljan EA, Hines SJ, Pande P, Corteling RL, Hicks C, Zbarsky V, et al. Implantation of c-mycER TAM immortalized human mesencephalic-derived clonal cell lines ameliorates behavior dysfunction in a rat model of Parkinson's disease. Stem Cells Dev 2009; 18:307-19.
15. De Filippis L, Lamorte G, Snyder EY, Malgaroli A, Vescovi AL. A novel, immortal and multipotent human neural stem cell line generating functional neurons and oligodendrocytes. Stem Cells 2007; 25:2312-21.
16. Kerosuo L, Piltti K, Fox H, Ngers-Loustau A, Hayry V, Eilers M, et al. Myc increases self-renewal in neural progenitor cells through Miz-1. J Cell Sci 2008; 121:3941-50.
17. Gil J, Kerai P, Lleonart M, Bernard D, Cigudosa JC, Peters G, et al. Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res 2005; 65:2179-85.
18. Thibodeaux CA, Liu X, Disbrow GL, Zhang Y, Rone JD, Haddad BR, et al. Immortalization and transformation of human mammary epithelial cells by a tumor-derived Myc mutant. Breast Cancer Res Treat 2009; 116:281-94.
19. Yaswen P, Stampfer MR. Molecular changes accompanying senescence and immortalization of cultured human mammary epithelial cells. Int J Biochem Cell Biol 2002; 34:1382-94.
20. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes Dev 1998; 12:1769-74.
21. Bazarov AV, Hines WC, Mukhopadhyay R, Beliveau A, Melodyev S, Zaslavsky Y, et al. Telomerase activation by c-Myc in human mammary epithelial cells requires additional genomic changes. Cell Cycle 2009; 8:3373-8.
22. Dimri GP. c-Myc and telomerase activation. Cell Cycle 2009; 8:3075-6.
23. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335:440-2.
24. Vaux DL. Early work on the function of Bcl-2, an interview with David Vaux. Cell Death Differ 2004; 11:28-32.
25. Cole MD. The myc oncogene: its role in transformation and differentiation. Annu Rev Genet 1986; 20:361-84.
26. Keath EJ, Caimi PG, Cole MD. Fibroblast lines expressing activated c-myc oncogenes are tumorigenic in nude mice and syngeneic animals. Cell 1984; 39:339-48.
27. Kelekar A, Cole MD. Tumorigenicity of fibroblast lines expressing the adenovirus E1a, cellular p53 or normal c-myc genes. Mol Cell Biol 1986; 6:7-14.
28. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001; 7:235-9. (Pubitemid 32148492)
29. Jang JW, Boxer RB, Chodosh LA. Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol Cell Biol 2006; 26:8109-21.
30. Alexander WS, Bernard O, Cory S, Adams JM. Lymphomagenesis in E mu-myc transgenic mice can involve ras mutations. Oncogene 1989; 4:575-81.
31. Liao DJ, Wang Y, Wu J, Adsay NV, Grignon D, Khanani F. Characterization of pancreatic lesions from MT-tgfalpha, Ela-myc and MT-tgfalpha/Elamyc single and double transgenic mice. J Carcinog 2006; 5:1-19.
32. Schaeffer BK, Terhune PG, Longnecker DS. Pancreatic carcinomas of acinar and mixed acinar/ductal phenotypes in Ela-1-myc transgenic mice do not contain c-K-ras mutations. Am J Pathol 1994; 145:696-701.
33. Kim SH, Nakagawa H, Navaraj A, Naomoto Y, Klein-Szanto AJ, Rustgi AK, et al. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res 2006; 66:10415-24.
34. Zhao JJ, Gjoerup OV, Subramanian RR, Cheng Y, Chen W, Roberts TM, et al. Human mammary epithelial cell transformation through the activation of phosphatidylinositol-3-kinase. Cancer Cell 2003; 3:483-95.
35. Zhao JJ, Roberts TM, Hahn WC. Functional genetics and experimental models of human cancer. Trends Mol Med 2004; 10:344-50.
36. Cowling VH, D'Cruz CM, Chodosh LA, Cole MD. c-myc Transforms Human Mammary Epithelial Cells through Repression of the Wnt Inhibitors DKK1 and SFRP1. Mol Cell Biol 2007; 27:5135-46.
37. Miliani de Marval PL, Macias E, Rounbehler R, Sicinski P, Kiyokawa H, Johnson DG, et al. Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol 2004; 24:7538-47. (Pubitemid 39121481)
38. Singh A, Sowjanya AP, Ramakrishna G. The wild-type Ras: Road ahead. FASEB J 2005; 19:161-9.
39. Spandidos DA, Wilkie NM. Malignant transformation of early passage rodent cells by a single mutated human oncogene. Nature 1984; 310:469-75.
40. Spandidos DA, Lang JC. Immortalization by truncated myc or ras genes and synergism between myc and ras genes in cell transformation. Anticancer Res 1989; 9:1149-52.
41. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001; 15:50-65.
42. Prober DA, Edgar BA. Interactions between Ras1, dMyc and dPI3K signaling in the developing Drosophila wing. Genes Dev 2002; 16:2286-99.
43. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14:2501-14.
44. Bazarov AV, Adachi S, Li SF, Mateyak MK, Wei S, Sedivy JM. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res 2001; 61:1178-86.
45. Kendall SD, Adam SJ, Counter CM. Genetically engineered human cancer models utilizing mammalian transgene expression. Cell Cycle 2006; 5:1074-9.
46. Kendall SD, Linardic CM, Adam SJ, Counter CM. A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Res 2005; 65:9824-8.
47. Sasaki R, Narisawa-Saito M, Yugawa T, Fujita M, Tashiro H, Katabuchi H, et al. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis 2009; 30:423-31.
48. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, et al. NFkappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003; 421:639-43.
49. Bolotin D, Fuchs E. Cancer: More than skin deep. Nature 2003; 421:594-5.
50. Lazarov M, Green CL, Zhang JY, Kubo Y, Dajee M, Khavari PA. Escaping G1 restraints on neoplasia - Cdk4 regulation by Ras and NFkappaB. Cell Cycle 2003; 2:79-80.
51. Cheng G, Lewis AE, Meinkoth JL. Ras stimulates aberrant cell cycle progression and apoptosis in rat thyroid cells. Mol Endocrinol 2002; 17:450-9.
52. Shao J, Sheng H, DuBois RN, Beauchamp RD. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem 2000; 275:22916-24.
53. Opitz OG, Suliman Y, Hahn WC, Harada H, Blum HE, Rustgi AK. Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest 2001; 108:725-32.
54. Goessel G, Quante M, Hahn WC, Harada H, Heeg S, Suliman Y, et al. Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc Natl Acad Sci USA 2005; 102:15599-604.
55. Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: From traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 2006; 95:211-8.
56. Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 2006; 66:11389-98. (Pubitemid 46009970)
57. Petty WJ, Dragnev KH, Dmitrovsky E. Cyclin D1 as a target for chemoprevention. Lung Cancer 2003; 41:155-61.
58. Poch B, Gansauge F, Schwarz A, Seufferlein T, Schnelldorfer T, Ramadani M, et al. Epidermal growth factor induces cyclin D1 in human pancreatic carcinoma: evidence for a cyclin D1-dependent cell cycle progression. Pancreas 2001; 23:280-7.
59. Ravitz MJ, Yan S, Dolce C, Kinniburgh AJ, Wenner CE. Differential regulation of p27 and cyclin D1 by TGFbeta and EGF in C3H 10T1/2 mouse fibroblasts. J Cell Physiol 1996; 168:510-20.
60. Strobl JS, Wonderlin WF, Flynn DC. Mitogenic signal transduction in human breast cancer cells. Gen Pharmacol 1995; 26:1643-9.
61. kip1 downregulation, passage through the restriction point and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1997; 17:5348-58.
62. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 2005; 37:745-9.
63. Lazarov M, Kubo Y, Cai T, Dajee M, Tarutani M, Lin Q, et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 2002; 8:1105-14.
64. Ink4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. Cancer Cell 2003; 4:301-10.
65. Nass SJ, Li M, Amundadottir LT, Furth PA, Dickson RB. Role for Bcl-xL in the regulation of apoptosis by EGF and TGFbeta1 in c-myc overexpressing mammary epithelial cells. Biochem Biophys Res Commun 1996; 227:248-56.
66. Elson A, Deng C, Campos-Torres J, Donehower LA, Leder P. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene 1995; 11:181-90.
67. McCormack SJ, Weaver Z, Deming S, Natarajan G, Torri J, Johnson MD, et al. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene 1998; 16:2755-66.
68. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009; 220:292-6.
69. ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995; 270:23589-97.
70. Mori K, Hirao E, Toya Y, Oshima Y, Ishikawa F, Nose K, et al. Competitive nuclear export of cyclin D1 and Hic-5 regulates anchorage dependence of cell growth and survival. Mol Biol Cell 2009; 20:218-32.
71. Resnitzky D. Ectopic expression of cyclin D1 but not cyclin E induces anchorage-independent cell cycle progression. Mol Cell Biol 1997; 17:5640-7. (Pubitemid 27357660)
72. Musgrove EA. Cyclins: Roles in mitogenic signaling and oncogenic transformation. Growth Factors 2006; 24:13-9.
73. Wang Y, Thakur A, Sun Y, Wu J, Biliran H, Bollig A, et al. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice. Cancer Res 2007; 67:3698-707.
74. Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F. Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol 2005; 70:461-7.
75. Yu Q, Ciemerych MA, Sicinski P. Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins. Oncogene 2005; 24:7114-9.
76. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 1999; 18:5321-33.
77. Bouchard C, Dittrich O, Kiermaier A, Dohmann K, Menkel A, Eilers M, et al. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev 2001; 15:2042-7.
78. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J 1999; 18:5310-20.
79. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, et al. Function of the c-Myc oncogenic transcription factor. Exp Cell Res 1999; 253:63-77.
80. Hydbring P, Larsson LG. Tipping the balance: Cdk2 enables Myc to suppress senescence. Cancer Res 2010; 70:6687-91.
81. Hirota K, Ohta K. Transcription of mRNA-type long non-coding RNAs (mlonRNAs) disrupts chromatin array. Commun Integr Biol 2009; 2:25-6.
82. Jansen-Durr P, Meichle A, Steiner P, Pagano M, Finke K, Botz J, et al. Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci USA 1993; 90:3685-9. (Pubitemid 23111432)
83. Marhin WW, Hei YJ, Chen S, Jiang Z, Gallie BL, Phillips RA, et al. Loss of Rb and Myc activation co-operate to suppress cyclin D1 and contribute to transformation. Oncogene 1996; 12:43-52.
84. Philipp A, Schneider A, Vasrik I, Finke K, Xiong Y, Beach D, et al. Repression of cyclin D1: a novel function of MYC. Mol Cell Biol 1994; 14:4032-43.
85. Cowling VH. Enhanced mRNA cap methylation increases cyclin D1 expression and promotes cell transformation. Oncogene 2010; 29:930-6.
86. di JB, Ulianich L, Racioppi L, D'Armiento F, Feliciello A, Pacifico F, et al. Serum withdrawal induces apoptotic cell death in Ki-ras transformed but not in normal differentiated thyroid cells. Biochem Biophys Res Commun 1995; 214:819-24.
87. Shirokawa JM, Elisei R, Knauf JA, Hara T, Wang J, Saavedra HI, et al. Conditional apoptosis induced by oncogenic ras in thyroid cells. Mol Endocrinol 2000; 14:1725-38.
88. Cheng G, Meinkoth JL. Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells. Oncogene 2001; 20:7334-41.
89. Bond J, Dawson T, Lemoine N, Wynford-Thomas D. Effect of serum growth factors and phorbol ester on growth and survival of human thyroid epithelial cells expressing mutant ras. Mol Carcinog 1992; 5:129-35.
90. Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ, et al. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA 2000; 97:2229-34.
91. Pawar SA, Szentirmay MN, Hermeking H, Sawadogo M. Evidence for a cancer-specific switch at the CDK4 promoter with loss of control by both USF and c-Myc. Oncogene 2004; 23:6125-35.
92. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999; 19:4672-83.
93. Obaya AJ, Mateyak MK, Sedivy JM. Mysterious liaisons: The relationship between c-Myc and the cell cycle. Oncogene 1999; 18:2934-41.
94. Obaya AJ, Kotenko I, Cole MD, Sedivy JM. The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) to facilitate the activation of Cdk4/6 and early G(1) phase progression. J Biol Chem 2002; 277:31263-9.
95. Vaque JP, Fernandez-Garcia B, Garcia-Sanz P, Ferrandiz N, Bretones G, Calvo F, et al. c-Myc inhibits Ras-mediated differentiation of pheochromocytoma cells by blocking c-Jun upregulation. Mol Cancer Res 2008; 6:325-39. (Pubitemid 351342420)
96. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors overexpressing MYC. Nat Med 2007; 13:820-7.
97. Sawey MJ, Hood AT, Burns FJ, Garte SJ. Activation of c-myc and c-K-ras oncogenes in primary rat tumors induced by ionizing radiation. Mol Cell Biol 1987; 7:932-5.
98. Taya Y, Hosogai K, Hirohashi S, Shimosato Y, Tsuchiya R, Tsuchida N, et al. A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer. EMBO J 1984; 3:2943-6.
99. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer 2000; 7:143-64.
100. Rose-Hellekant TA, Wentworth KM, Nikolai S, Kundel DW, Sandgren EP. Mammary Carcinogenesis Is Preceded by Altered Epithelial Cell Turnover in Transforming Growth Factor-{alpha} and c-myc Transgenic Mice. Am J Pathol 2006; 169:1821-32.
101. Calvisi DF, Thorgeirsson SS. Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol 2005; 33:181-4.
102. Thorgeirsson SS, Santoni-Rugiu E. Interaction of c-myc with transforming growth factor alpha and hepatocyte growth factor in hepatocarcinogenesis. Mutat Res 1997; 376:221-34.
103. Thorgeirsson SS, Factor VM, Snyderwine EG. Transgenic mouse models in carcinogenesis research and testing. Toxicol Lett 2000; 112:553-5.
104. Liao JD, Adsay NV, Khannani F, Grignon D, Thakur A, Sarkar FH. Histological complexities of pancreatic lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human pancreatic cancer. Histol Histopathol 2007; 22:661-76.
105. Perry JE, Grossmann ME, Tindall DJ. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate 1998; 35:117-24.
106. Yan YX, Nakagawa H, Lee MH, Rustgi AK. Transforming growth factor-alpha enhances cyclin D1 transcription through the binding of early growth response protein to a cis-regulatory element in the cyclin D1 promoter. J Biol Chem 1997; 272:33181-90. (Pubitemid 28023664)
107. Liao DJ, Natarajan G, Deming SL, Jamerson MH, Johnson M, Chepko G, et al. Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis. Oncogene 2000; 19:1307-17.
108. Sandgren EP, Schroeder JA, Qui TH, Palmiter RD, Brinster RL, Lee DC. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res 1995; 55:3915-27.
109. Roussel MF, Theodoras AM, Pagano M, Sherr CJ. Rescue of defective mitogenic signaling by D-type cyclins. Proc Natl Acad Sci USA 1995; 92:6837-41.
110. Lovec H, Sewing A, Lucibello FC, Muller R, Moroy T. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 1994; 9:323-6.
111. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994; 13:2124-30.
112. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J 1994; 13:3487-95.
113. Kwek SS, Roy R, Zhou H, Climent J, Martinez-Climent JA, Fridlyand J, et al. Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene 2009; 28:1892-903.
114. Suen TC, Hung MC. c-myc reverses neu-induced transformed morphology by transcriptional repression. Mol Cell Biol 1991; 11:354-62.
115. Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allelespecific binding to potentiate tumorigenesis. Cancer Res 2006; 66:5330-7. (Pubitemid 43844958)
116. Barr LF, Campbell SE, Diette GB, Gabrielson EW, Kim S, Shim H, et al. c-Myc suppresses the tumori-genicity of lung cancer cells and downregulates vascular endothelial growth factor expression. Cancer Res 2000; 60:143-9. (Pubitemid 30058744)
117. Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004; 6:577-86. (Pubitemid 40017701)
118. Podsypanina K, Politi K, Beverly LJ, Varmus HE. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci USA 2008; 105:5242-7. (Pubitemid 351738541)
119. Tilli MT, Furth PA. Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence. Breast Cancer Res 2003; 5:202-5.
120. Tran PT, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, et al. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One 2008; 3:2125.
121. Pelengaris S, Abouna S, Cheung L, Ifandi V, Zervou S, Khan M. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumors of pancreatic islets and skin epidermis. BMC Biol 2004; 2:26. (Pubitemid 40251682)
122. Glockner S, Buurman H, Kleeberger W, Lehmann U, Kreipe H. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 2002; 82:1419-26. (Pubitemid 35191545)
123. Liao DJ, Dickson RB. Cell death in MMTV-c-myc transgenic mouse mammary tumors may not be typical apoptosis. Lab Invest 2003; 83:1437-49.
124. Biliran H Jr, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 2005; 11:6075-86. (Pubitemid 41170340)
125. Biliran H Jr, Banerjee S, Thakur A, Xu H, Heng H, Thakur A, et al. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappaB activity in pancreatic cancer cells. Clin Cancer Res 2007; 13:2811-21. (Pubitemid 46788051)
126. Diehl JA, Benzeno S. Cyclin D1 and pancreatic carcinoma: a proliferative agonist and chemotherapeutic antagonist. Clin Cancer Res 2005; 11:5665-7.
127. Robles AI, Rodriguez-Puebla ML, Glick AB, Trempus C, Hansen L, Sicinski P, et al. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 1998; 12:2469-74.
128. Rodriguez-Puebla ML, Robles AI, Conti CJ. ras activity and cyclin D1 expression: an essential mechanism of mouse skin tumor development. Mol Carcinog 1999; 24:1-6.
129. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001; 411:1017-21.
130. Jiang W, Kahn SM, Zhou P, Zhang YJ, Cacace AM, Infante AS, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 1993; 8:3447-57.
131. Michaux L, Wlodarska I, Theate I, Stul M, Scheiff JM, Deneys V, et al. Coexistence of BCL1/CCND1 and CMYC aberrations in blastoid mantle cell lymphoma: a rare finding associated with very poor outcome. Ann Hematol 2004; 83:578-83. (Pubitemid 39209181)
132. Shiina H, Igawa M, Shigeno K, Terashima M, Deguchi M, Yamanaka M, et al. Beta-catenin mutations correlate with overexpression of C-myc and cyclin D1 Genes in bladder cancer. J Urol 2002; 168:2220-6.
133. Butt AJ, Caldon CE, McNeil CM, Swarbrick A, Musgrove EA, Sutherland RL. Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol 2008; 630:189-205.
134. Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, et al. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res 2006; 66:11967-74. (Pubitemid 46094210)
135. 2 phase. Cell Cycle 2002; 1:50-8.
136. Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003; 15:158-63.
137. Satyanarayana A, Kaldis P. Mammalian cell cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009; 28:2925-39.
138. Kehn K, Berro R, Alhaj A, Bottazzi ME, Yeh WI, Klase Z, et al. Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells. Oncogene 2007; 26:5060-9. (Pubitemid 47206950)
139. Wang C, Li Z, Lu Y, Du R, Katiyar S, Yang J, et al. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc Natl Acad Sci USA 2006; 103:11567-72.
140. Aggarwal P, Vaites LP, Kim JK, Mellert H, Gurung B, Nakagawa H, et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell 2010; 18:329-40.
141. Liu F, Matsuura I. Inhibition of Smad antiproliferative function by CDK phosphorylation. Cell Cycle 2005; 4:63-6.
142. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430:226-31.
143. Lin HM, Zhao L, Cheng SY. Cyclin D1 Is a Ligand-independent Co-repressor for Thyroid Hormone Receptors. J Biol Chem 2002; 277:28733-41.
144. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, et al. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 2001; 15:797-811. (Pubitemid 32411317)
145. Fu M, Wang C, Rao M, Wu X, Bouras T, Zhang X, et al. Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J Biol Chem 2005; 280:29728-42.
146. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol 2003; 23:6159-73.
147. Reddy HK, Mettus RV, Rane SG, Grana X, Litvin J, Reddy EP. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res 2005; 65:10174-8. (Pubitemid 41743706)
148. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006; 9:23-32.
149. Morrison BW, Leder P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994; 9:3417-26.
150. Cowling VH, Cole MD. Turning the tables: Myc activates Wnt in breast cancer. Cell Cycle 2007; 6:2625-7.
151. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 2000; 20:672-83.
152. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 1994; 91:709-13.
153. Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006; 9:13-22.
154. INK4A as upstream regulators of Myc. Oncogene 1997; 15:179-92.
155. Zwicker J, Brusselbach S, Jooss KU, Sewing A, Behn M, Lucibello FC, et al. Functional domains in cyclin D1: pRb-kinase activity is not essential for transformation. Oncogene 1999; 18:19-25.
156. 1 cyclin-dependent kinases in the absence of retinoblastoma protein phosphorylation. Curr Biol 1997; 7:709-12.
157. Blain SW. Switching cyclin D-Cdk4 kinase activity on and off. Cell Cycle 2008; 7:892-8.
158. Sumrejkanchanakij P, Tamamori-Adachi M, Matsunaga Y, Eto K, Ikeda MA. Role of cyclin D1 cytoplasmic sequestration in the survival of postmitotic neurons. Oncogene 2003; 22:8723-30.
159. Sumrejkanchanakij P, Eto K, Ikeda MA. Cytoplasmic sequestration of cyclin D1 associated with cell cycle withdrawal of neuroblastoma cells. Biochem Biophys Res Commun 2006; 340:302-8. (Pubitemid 41827681)
160. Albrecht JH, Rieland BM, Nelsen CJ, Ahonen CL. Regulation of G(1) cyclin-dependent kinases in the liver: role of nuclear localization and p27 sequestration. Am J Physiol 1999; 277:1207-16.
161. Ahamed S, Foster JS, Bukovsky A, Diehl JA, Wimalasena J. Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells. Mol Carcinog 2002; 34:45-58.
162. Alao JP, Gamble SC, Stavropoulou AV, Pomeranz KM, Lam EW, Coombes RC, et al. The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol Cancer 2006; 5:7.
163. Alao JP. The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007; 6:24.
164. De FM, Fedele V, De LL, Penta R, Cottone G, Cavallotti I, et al. Evaluation of cyclin D1 expression and its subcellular distribution in mouse tissues. J Anat 2004; 205:405-12.
165. Tamamori-Adachi M, Ito H, Sumrejkanchanakij P, Adachi S, Hiroe M, Shimizu M, et al. Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation. Circ Res 2003; 92:12-9.
166. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, et al. The p21(Cip1) and p27(Kip1) CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999; 18:1571-83.
167. Murakami H, Horihata M, Andojo S, Yoneda-Kato N, Kato JY. Isolation and characterization of cytoplasmic cyclin D1 mutants. FEBS Lett 2009; 583:1575-80.
168. Freedman VH, Shin SI. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 1974; 3:355-9.
169. Miller FR. Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia 2000; 5:379-91.
170. Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, et al. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One 2010; 5:9201.
171. Podsypanina K, Du YC, Jechlinger M, Beverly LJ, Hambardzumyan D, Varmus H. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008; 321:1841-4.
172. Weinberg RA. Leaving home early: reexamination of the canonical models of tumor progression. Cancer Cell 2008; 14:283-4.
173. Ito N, Hasegawa R, Imaida K, Hirose M, Asamoto M, Shirai T. Concepts in multistage carcinogenesis. Crit Rev Oncol Hematol 1995; 21:105-33.
174. Hennings H, Glick AB, Greenhalgh DA, Morgan DL, Strickland JE, Tennenbaum T, et al. Critical aspects of initiation, promotion and progression in multistage epidermal carcinogenesis. Proc Soc Exp Biol Med 1993; 202:1-8.
175. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992; 54:63-128.
176. Miller EC, Miller JA. Mechanisms of chemical carcinogenesis. Cancer 1981; 47:1055-64.
177. Briand P. Hormone-dependent mammary tumors in mice and rats as a model for human breast cancer (review). Anticancer Res 1983; 3:273-81.
178. Cutts JH. Estrogen-induced breast cancer in the rat. Proc Can Cancer Conf 1966; 6:50-68.
179. Jordan VC. Laboratory models of breast cancer to aid the elucidation of antiestrogen action. J Lab Clin Med 1987; 109:267-77.
180. Liao DJ, Dickson RB. Roles of androgens in the development, growth and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 2002; 80:175-89.
181. McGuire WL, Chamness GC, Costlow ME, Shepherd RE. Hormone dependence in breast cancer. Metabolism 1974; 23:75-100.
182. Noble RL, Cutts JH. Mammary tumors of the rat: a review. Cancer Res 1959; 19:1125-39.
183. Noble RL. Prostate carcinoma of the Nb rat in relation to hormones. Int Rev Exp Pathol 1982; 23:113-59.
184. Cutts JH. Enzyme activities in regressing estrone-induced mammary tumors of the rat. Cancer Res 1973; 33:1235-7.
185. Cutts JH, Froude GC. Regression of estrone-induced mammary tumors in the rat. Cancer Res 1968; 28:2413-8.
186. Huggins C. Endocrine-induced regression of cancers. Am J Surg 1978; 136:233-8.
187. Huggins C, Oka H. Regression of stem-cell erythroblastic leukemia after hypophysectomy. Cancer Res 1972; 32:239-42.
188. Huggins CB, Ueda N. Regression of myelocytic leukemia in rats after hypophysectomy. Proc Natl Acad Sci USA 1984; 81:598-601.
189. Huggins C. Endocrine-induced regression of cancers. Cancer Res 1967; 27:1925-30.
190. Shvemberger IN. Conversion of malignant cells into normal ones. Int Rev Cytol 1986; 103:341-86.
191. Felsher DW. Tumor dormancy and oncogene addiction. APMIS 2008; 116:629-37.
192. Hengstler JG, Bockamp EO, Hermes M, et al. Oncogene-blocking therapies: new insights from conditional mouse tumor models. Curr Cancer Drug Targets 2006; 6:603-12.
193. Felsher DW. Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models. Cell Cycle 2006; 5:1808-11.
194. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7:834-46.